AstraZeneca Plc (NASDAQ:AZN) released high-level results from the MATTERHORN Phase 3 trial evaluating Imfinzi (durvalumab) as ...
GlobalData on MSN3d
AstraZeneca reports positive outcomes from trial of ImfinziAstraZeneca has reported positive “high-level” outcomes from the randomised Phase III MATTERHORN trial of Imfinzi (durvalumab ...
AstraZeneca is preparing to talk to the FDA about a potential new use of its immunotherapy Imfinzi after a pivotal study in ...
Preliminary trial results demonstrated that Imfinzi plus chemo improved event-free survival in resectable early-stage gastric ...
Medpage Today on MSN7h
NCI Flags 'Cancer Moonshot'; Dr. Hologram Will See You; Fraud Crackdown ContinuesThe American Cancer Society awarded its 2025 Medal of Honor to W. Kimryn Rathmell, MD, PhD, renowned kidney cancer expert and ...
Imfinzi is one of AstraZeneca’s key growth drivers for 2025, with potential approvals in stomach and bladder cancers. The ...
AstraZeneca (AZ) has shared positive results from a late-stage trial of its Imfinzi (durvalumab)-based perioperative regimen ...
A treatment combining AstraZeneca’s (LSE: AZN) immunotherapy Imfinzi (durvalumab) with chemotherapy has significantly reduced ...
The Food and Drug Administration (FDA) has approved Imfinzi (durvalumab) for adults with limited-stage small cell lung cancer ...
Imfinzi plus chemotherapy significantly improved event-free survival in resectable Stage II-IVA gastric and GEJ cancer patients. A strong trend in overall survival benefit was observed ...
AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended for approval in the European Union (EU) for the treatment of adults with resectable non-small cell lung cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback